Product Information
NAPROXEN 250 MG TABLET is a generic product labeled by ScieGen Pharmaceuticals, Inc., priced at $0.0436 per EA under NDC 50228043401. Its NADAC has been published 325 times since Jul 15, 2020.
FDA first approved this application on Feb 21, 2020. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
250 mg/1
Manufacturer
ScieGen Pharmaceuticals, Inc.NDC
50228043401
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
NAPROXENApproval Type
Generic (ANDA)
FDA Application
ANDA212517FDA Approved
2/21/2020
TE Code
AB
On Market Since
3/1/2020
Pharmacological Classes
Price Statistics
The NADAC for NAPROXEN 250 MG TABLET has been published 325 times since Jul 15, 2020, and over the history we have for it it has declined 21.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0436 per EA |
|---|---|
| All-time high | $0.0656 (Mar 13, 2024) |
| All-time low | $0.0311 (Jul 17, 2024) |
| 52-week high | $0.0474 |
| 52-week low | $0.0434 |
| Median price | $0.0521 |
| Average price | $0.0510 |
| Largest weekly change | +50.1% (Aug 21, 2024) |
| Weeks tracked | 325 |
| Tracking since | Jul 15, 2020 |
Generic Alternatives
The matcher finds 8 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
ScieGen Pharmaceuticals, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Naproxen market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Nonsteroidal Anti-inflammatory Drug class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of NAPROXEN 250 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for NAPROXEN 250 MG TABLET, manufactured by ScieGen Pharmaceuticals, Inc., is $0.0436 per EA (NDC 50228043401), effective Sep 30, 2026.
How has the price of NAPROXEN 250 MG TABLET changed over time?
Over the history we have for it, the NADAC for NAPROXEN 250 MG TABLET has declined 21.7%. It has been tracked across 325 weekly CMS publications since Jul 15, 2020.
What are the highest and lowest recorded NADAC prices for NAPROXEN 250 MG TABLET?
Since Jul 15, 2020, the NADAC for NAPROXEN 250 MG TABLET has ranged from a low of $0.0311 (Jul 17, 2024) to a high of $0.0656 (Mar 13, 2024), with a median of $0.0521 per EA.
Are there cheaper alternatives to NAPROXEN 250 MG TABLET?
8 manufacturers publish a NADAC-priced product with the same active ingredient and strength as NAPROXEN 250 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures NAPROXEN 250 MG TABLET?
NAPROXEN 250 MG TABLET (NDC 50228043401) is labeled by ScieGen Pharmaceuticals, Inc., and CMS classifies it as a generic product.